← Mineralys Therapeutics, Inc. (MLYS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Mineralys Therapeutics, Inc. (MLYS)
Pharmaceutical Preparations · market cap $2.5B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
4
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Mineralys Therapeutics (MLYS) is a clinical-stage pharmaceutical company with a market cap of ~$2.25B and 51 employees, built almost entirely around lorundrostat, an aldosterone synthase inhibitor in Phase 3 for hypertension with a PDUFA date on or around December 31, 2026. The company carries $112.8M in cash against an ~8.6-month runway, creating a tight funding window ahead of its regulatory decision.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-01Regulatoryimp 3/10
- 2026-12-22PDUFA · Lorundrostatimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| lorundrostat Dose 1 | Phase 3 | Hypertension |
| MLS-101 (Part I) | Phase 2 | Hypertension, Renal |
| Lorundrostat | Phase 3 | Obstructive Sleep Apnea |
| lorundrostat Dose 2 | Phase 2 | Hypertension |
Price & technical context
3-month
-18.4%
6-month
-11.9%
12-month
-40.3%
52-wk range
$22.50–$47.33
vs 50-day MA
-11.5%
vs 200-day MA
-16.4%
Realized vol
58.9%
Max drawdown
-52.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MLYS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.